Bioline RX Ltd Sponsored ADR (BLRX) AI Stock Analysis

2,505 Followers

Top Page

Bioline RX Ltd Sponsored ADR

(NASDAQ:BLRX)

34Underperform

BioLineRx Ltd's overall stock score reflects significant revenue growth and operational improvements, yet it remains under pressure from negative profitability and high leverage. Technical indicators suggest a bearish trend, while valuation metrics highlight concerns over negative earnings and absence of dividends. Despite positive aspects, the stock faces multiple challenges that weigh on its attractiveness.

Positive Factors

Financial Performance

The company is on sounder financial footing following cessation of U.S. commercial operations, which resulted in an ~70% reduction in operating expenses.

Investment Activity

$9M equity investment received from funds managed by Highbridge Capital Management to support pipeline expansion.

Revenue and Sales

APHEXDA continues expanding market share, achieving 10% market share of total CXCR4 inhibitor usage in the U.S.

Negative Factors

Clinical Trials

Full enrollment in the Phase IIb trial of motixafortide in pancreatic ductal adenocarcinoma is not expected until 2027, and pancreatic cancer is a particularly intractable disease.

Market Sentiment

The stock is expected to remain range bound until pipeline assets are in-licensed and/or motixafortide generates additional favorable data in pancreatic cancer and/or gene therapy indications.

Bioline RX Ltd Sponsored ADR (BLRX) vs. S&P 500 (SPY)

Market Cap

$10.27M

Dividend YieldN/A

Average Volume (3M)31.05K

Price to Earnings (P/E)―

Beta (1Y)1.52

Revenue Growth502.92%

EPS Growth88.20%

CountryUS

Employees28

SectorHealthcare

Sector Strength71

IndustryBiotechnology

Share Statistics

EPS (TTM)-4.48

Shares Outstanding3,721,003

10 Day Avg. Volume40,235

30 Day Avg. Volume31,052

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)2.65

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$26.00

Price Target Upside799.65% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bioline RX Ltd Sponsored ADR Business Overview & Revenue Model

Company DescriptionBioline RX Ltd Sponsored ADR (BLRX) is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of serious medical conditions. The company is primarily engaged in the discovery and clinical development of novel compounds, currently targeting areas such as oncology and immunology. Bioline RX operates through research and development activities and its lead product candidates are aimed at addressing unmet medical needs.

How the Company Makes MoneyBioline RX Ltd generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties on sales generated from any successfully commercialized products. The company may also receive funding from grants or government support for its research endeavors. Bioline RX's financial performance is significantly influenced by the progress of its clinical trials, regulatory approvals, and the successful commercialization of its therapeutic candidates.

Bioline RX Ltd Sponsored ADR Financial Statement Overview

Summary

BLRX demonstrates growth in revenue but continues to face profitability challenges and relies heavily on borrowing, typical for a biotechnology firm in developmental stages. The current financial trajectory suggests a need for careful management of resources to achieve sustainable operations.

Income Statement

Neutral

BLRX showed a significant increase in revenue in the TTM (Trailing-Twelve-Months), growing from a low base. However, the company remains unprofitable with negative EBIT and net income margins, indicating ongoing operational challenges in achieving profitability.

Balance Sheet

Neutral

The balance sheet reveals a high debt-to-equity ratio, suggesting leveraged operations, yet a reasonable equity ratio indicates some level of asset backing. The company's equity has decreased over recent periods, potentially impacting its financial stability.

Cash Flow

Negative

Free cash flow remains negative, reflecting cash burn, typical in biotechnology for research and development. This is offset by positive financing cash flows, indicating reliance on external funding. The operating cash flow to net income ratio shows divergence, highlighting cash flow challenges.

TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Breakdown
Income Statement		Total Revenue
21.99M	4.80M	0.00	0.00	0.00	0.00
	Gross Profit
15.13M	1.11M	-654.00K	-702.00K	-934.00K	-940.00K
	EBIT
-27.84M	-49.69M	-29.16M	-24.78M	-22.93M	-28.11M
	EBITDA
-12.36M	-57.06M	-28.50M	-25.35M	-21.99M	-27.17M
	Net Income Common Stockholders
-19.92M	-60.61M	-18.87M	-28.14M	-30.93M	-26.81M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
25.97M	42.99M	51.08M	57.13M	22.59M	27.49M
	Total Assets
29.34M	63.92M	76.38M	81.39M	47.29M	53.57M
	Total Debt
109.56K	11.59M	12.32M	4.65M	7.68M	10.46M
	Net Debt
-8.58M	7.34M	1.74M	-8.34M	-9.15M	5.16M
	Total Liabilities
6.81M	50.70M	25.54M	13.30M	25.26M	20.19M
	Stockholders Equity
22.53M	13.22M	50.84M	68.09M	22.03M	33.38M
Cash Flow		Free Cash Flow
-30.35M	-22.91M	-26.56M	-23.67M	-23.21M	-22.74M
	Operating Cash Flow
-30.27M	-22.61M	-26.24M	-23.57M	-23.21M	-22.67M
	Investing Cash Flow
-2.18M	1.44M	4.01M	-38.22M	16.67M	5.26M
	Financing Cash Flow
33.51M	15.06M	20.44M	57.75M	17.87M	19.19M

Bioline RX Ltd Sponsored ADR Technical Analysis

Technical Analysis Sentiment

Negative

Last Price2.89

Price Trends

50DMA

3.25

Negative

100DMA

5.95

Negative

200DMA

15.08

Negative

Market Momentum

MACD

-0.23

Negative

RSI

45.92

Neutral

STOCH

47.00

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLRX, the sentiment is Negative. The current price of 2.89 is below the 20-day moving average (MA) of 3.00, below the 50-day MA of 3.25, and below the 200-day MA of 15.08, indicating a bearish trend. The MACD of -0.23 indicates Negative momentum. The RSI at 45.92 is Neutral, neither overbought nor oversold. The STOCH value of 47.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLRX.

Bioline RX Ltd Sponsored ADR Risk Analysis

Bioline RX Ltd Sponsored ADR disclosed 43 risk factors in its most recent earnings report. Bioline RX Ltd Sponsored ADR reported the most risks in the “Tech & Innovation” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Bioline RX Ltd Sponsored ADR Peers Comparison

Overall Rating

UnderperformOutperform

Sector (48)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.46B	1.17	-47.75%	2.67%	19.50%	0.61%
ADXN	45 Neutral	$11.25M	1.07	-85.36%	―	-70.05%	―
RNAZ	42 Neutral	$9.43M	―	-490.03%	―	―	98.97%
TXMD	40 Underperform	$11.46M	―	-8.16%	―	35.25%	81.05%
APRE	38 Underperform	$8.51M	―	-66.65%	―	157.63%	40.52%
BLRX	34 Underperform	$10.27M	―	-69.11%	―	502.92%	88.20%
ABVC	33 Underperform	$11.86M	―	-90.91%	―	-31.04%	74.62%

* Healthcare Sector Average

Performance Comparison

BLRX

Bioline RX Ltd Sponsored ADR

2.89

-22.71

-88.71%

TXMD

TherapeuticsMD

1.03

-0.92

-47.18%

ABVC

ABVC BioPharma, Inc.

0.91

-0.18

-16.51%

APRE

Aprea Therapeutics

1.58

-4.32

-73.22%

ADXN

Addex Therapeutics

6.97

-17.78

-71.84%

RNAZ

TransCode Therapeutics

0.41

-17.29

-97.68%

Bioline RX Ltd Sponsored ADR Earnings Call Summary

Earnings Call Date: Mar 31, 2025 | % Change Since: -5.25% | Next Earnings Date: May 21, 2025

Earnings Call Sentiment Positive

The earnings call highlights BioLineRx's transformational licensing agreement and significant revenue growth, indicating a positive outlook with a strong financial position and promising clinical developments. However, the shutdown of U.S. operations and challenges in PDAC development highlight ongoing strategic adjustments.

Highlights

Transformational Licensing Agreement with Ayrmid Pharma

BioLineRx executed an exclusive license agreement with Ayrmid Pharma Ltd. for motixafortide, generating $10 million in upfront payments and eligibility for $87 million in potential milestones, along with 18% to 23% sales royalties.

Significant Revenue Growth

Total revenues for 2024 were $28.9 million, a 502.1% increase from $4.8 million in 2023, driven by upfront payments and milestones from licensing agreements.

Operational Streamlining and Cost Reduction

BioLineRx reduced operating cash burn by approximately 70%, from over $40 million annually to about $12 million, following the shutdown of U.S. operations and headcount reduction in Israel.

Strong Financial Position

BioLineRx ended 2024 with $29 million in pro forma cash and a cash runway projected to fund operations through the second half of 2026.

Promising Clinical Developments in Sickle Cell Disease

Positive initial results from motixafortide trials in sickle cell disease, showing the potential to mobilize enough stem cells for gene therapies in fewer cycles.

Lowlights

Shutdown of U.S. Operations

BioLineRx shut down its U.S. operations as part of a strategic shift, impacting its commercial team and potentially reducing direct market engagement.

Challenges in PDAC Development

Development of motixafortide in pancreatic ductal carcinoma (PDAC) remains challenging, with full enrollment in the Phase 2b study not expected until 2027.

High Sales and Marketing Expenses

Sales and marketing expenses for 2024 were $23.6 million, only a slight decrease of 6.7% from 2023, despite the shutdown of U.S. commercial operations.

Company Guidance

During the BioLineRx Fourth Quarter and Full Year 2024 Financial Results Conference Call, CEO Phil Serlin highlighted key metrics reflecting the company's strategic shift and financial performance. BioLineRx executed an exclusive license agreement with Ayrmid Pharma Ltd. for motixafortide, generating $10 million in upfront payments and making the company eligible for $87 million in potential milestones and sales royalties ranging from 18% to 23%. The company reported total revenues of $28.9 million for 2024, a 502.1% increase from 2023. The shutdown of U.S. operations and headcount reduction in Israel reduced annual operating cash burn by 70%, from over $40 million to approximately $12 million. Additionally, BioLineRx ended the year with pro forma cash of $29 million and a cash runway projected to fund operations through the second half of 2026. The company is focused on expanding its pipeline by evaluating early clinical stage and late pre-clinical stage therapeutic assets in oncology and rare diseases, leveraging its drug development expertise.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.